Project Details
Projekt Print View

TRR 240:  Platelets – Molecular, cellular and systemic functions in health and disease

Subject Area Biology
Medicine
Term from 2018 to 2023
Website Homepage
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 374031971
 
Besides their central role in haemostasis and thrombosis, platelets are increasingly recognised as versatile effector cells in inflammation, the innate and adaptive immune response, extracellular matrix reorganisation and fibrosis, maintenance of barrier and organ integrity, and host response to pathogens. These platelet functions, referred to as thrombo-inflammation and immunothrom-bosis, have gained major attention in the COVID-19 pandemic, where patients develop an inflammatory disease state with severe and life-threatening thromboembolic complications. In the CRC/TR 240, a highly interdisciplinary team of basic, translational and clinical scientists explores these emerging roles of platelets with the aim to develop novel treatment concepts for cardio-vascular disorders and beyond. In the first funding period we have i) unravelled mechanisms leading to life-threatening thromboembolic complications following vaccination against SARS-CoV-2 with adenoviral vector-based vaccines, ii) identified unrecognised functions of platelet receptors and their regulation, offering new potential targets for pharmacological intervention and iii) developed new methodology to study the biology of megakaryocytes (MKs), the precursor cells of platelets in the bone marrow, which lay the foundation for the modulation of platelet biogenesis and function. In the second funding period, building on the unique expertise of our research network, we will continue to work in the following complementary fields: (A) Cell biology of megakaryocytes and platelets and (B) Platelets as regulators and effectors in disease. We will expand on what has been achieved, focussing on the communication of MKs and platelets with other cell types under (patho-)physiological conditions. Based on major findings of the first funding period, we have strengthened the CRC/TR by integrating new groups and projects focussing on immune-related thrombosis and infectious diseases to identify new MK-/platelet-specific targets for better diagnostics and improved treatment options. To achieve this ultimate goal, we follow a comprehensive approach starting out from in vitro systems and animal models to clinical research with large prospective patient cohorts and data-/biobanking.
DFG Programme CRC/Transregios

Completed projects

Co-Applicant Institution Eberhard Karls Universität Tübingen
Participating University Universität Greifswald; Universität Wien
 
 

Additional Information

Textvergrößerung und Kontrastanpassung